首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   554篇
  免费   68篇
  国内免费   4篇
耳鼻咽喉   20篇
儿科学   29篇
妇产科学   14篇
基础医学   227篇
口腔科学   37篇
临床医学   33篇
内科学   60篇
皮肤病学   3篇
神经病学   7篇
特种医学   5篇
外科学   26篇
综合类   51篇
预防医学   9篇
眼科学   1篇
药学   83篇
  1篇
中国医学   15篇
肿瘤学   5篇
  2024年   2篇
  2023年   10篇
  2022年   6篇
  2021年   16篇
  2020年   17篇
  2019年   24篇
  2018年   25篇
  2017年   25篇
  2016年   34篇
  2015年   20篇
  2014年   33篇
  2013年   53篇
  2012年   35篇
  2011年   46篇
  2010年   27篇
  2009年   26篇
  2008年   27篇
  2007年   28篇
  2006年   34篇
  2005年   12篇
  2004年   25篇
  2003年   17篇
  2002年   6篇
  2001年   6篇
  2000年   4篇
  1999年   8篇
  1998年   11篇
  1997年   10篇
  1996年   4篇
  1995年   4篇
  1994年   5篇
  1993年   2篇
  1992年   5篇
  1991年   4篇
  1990年   4篇
  1989年   1篇
  1988年   2篇
  1987年   2篇
  1986年   2篇
  1985年   1篇
  1984年   1篇
  1981年   2篇
排序方式: 共有626条查询结果,搜索用时 15 毫秒
621.

Purpose

The SQ tree sublingual immunotherapy (SLIT)-tablet containing allergen extracts with the major allergen Bet v 1 from birch pollen is currently being developed for the treatment of tree pollen–induced allergic rhinitis/conjunctivitis with or without asthma. The aim of this Phase II trial was to investigate the dose-related efficacy and safety of the SQ tree SLIT-tablet.

Methods

This study was a randomized, parallel-group, double-blind, placebo-controlled, multi-national trial conducted in Europe. A total of 637 participants were randomized equally to receive placebo or treatment with the SQ tree SLIT-tablet in doses of 0.5, 1, 2, 4, 7, or 12 development units (DU). Treatment was initiated ~16 weeks before onset of the 2013 birch pollen season (BPS) and was continued throughout the BPS with a total duration of at least 6 months. During the BPS and tree pollen season (TPS), subjects assessed rhinoconjunctivitis symptoms and medication use on a daily basis in an electronic diary; weekly assessments of rhinoconjunctivitis quality of life were also made.

Findings

Analysis of the average daily symptom score during the BPS and the TPS showed that the difference between active treatment and placebo was statistically significant for the 7 DU group (BPS, P = 0.02; TPS, P = 0.03), with no clear dose–response relationship. All doses of the SQ tree SLIT-tablet induced changes from baseline in birch-specific IgE and IgG4 that were statistically significant compared with placebo at all time points assessed (P < 0.0001) with a clear dose-response relationship for birch specific IgG4. In general, the SQ tree SLIT-tablet was well tolerated, with the majority of treatment-related adverse events (≥95%) being mild or moderate in severity. The most frequently reported treatment-related adverse events were generally related to the sublingual administration of the tablet (ie, they occurred in the oral cavity).

Implications

The results from this trial suggest that the SQ tree SLIT-tablet in doses up to 12 DU has a tolerability profile suitable for at-home administration. The immunomodulatory changes indicate a dose–response relationship, but clinical efficacy parameters were inconclusive, probably due to low pollen counts, emphasizing the importance of pollen exposure for the outcome of a pollen allergy immunotherapy trial. EudraCT no: 2012-000031-59.  相似文献   
622.
  1. Download : Download high-res image (386KB)
  2. Download : Download full-size image
  相似文献   
623.
624.
625.
BackgroundIn the 1950s, Hokin conducted initial studies on phosphoinositide turnover/cycle in salivary glandular cells. From these studies, the idea emerged that receptor-mediated changes in intramembranous levels of phosphoinositides represent an early step in the stimulus-response pathway. Based on this idea and the general view that knowledge of the exact localization of a given endogenous molecule in cells in situ is important for understanding its functional significance, we have reviewed available information about the localization of several representative phosphoinositide-signaling molecules in the salivary glands in situ in mice.HighlightWe focused on phosphatidylinositol 4-kinase, phosphatidylinositol 4 phosphate 5-kinase α, β, γ, phospholipase Cβ, muscarinic cholinoceptors 1 and 3, diacylglycerol kinase ζ, phospholipase D1 and 2, ADP-ribosylation factor 6 and its exchange factors for Arf6, and cannabinoid receptors. These molecules individually exhibit differential localization in a spatiotemporal manner in the exocrine glands, making it possible to deduce their functional significance, such as their involvement in secretion and cell differentiation.ConclusionAlthough phosphoinositide-signaling molecules whose in situ localization in glandular cells has been clarified are still limited, the obtained information on their localization suggests that their functional significance is more valuable in glandular ducts than in acini. It thus suggests the necessity of greater attention to the ducts in their physio-pharmacological analyses. The purpose of this review is to encourage more in situ localization studies of phosphoinositide-signaling molecules with an aim to further understand their possible involvement in the pathogenesis of salivary gland diseases.  相似文献   
626.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号